Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2/3 1Phase 2 1

Status

Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 9INDUSTRY 3FED 1

Study Type

Interventional 3

Sponsor

Conditions

Neoplasms 3216Carcinoma, Non-Small-Cell Lung 2729Breast Neoplasms 2551Colorectal Neoplasms 1463Prostatic Neoplasms 1307Neoplasm Metastasis 1301Multiple Myeloma 1112Melanoma 1103Ovarian Neoplasms 1006Lung Neoplasms 945Recurrence 924Leukemia, Myeloid, Acute 879Pancreatic Neoplasms 833Lymphoma, Non-Hodgkin 767Lymphoma 713Stomach Neoplasms 692Carcinoma, Renal Cell 660Carcinoma, Hepatocellular 647Leukemia, Lymphocytic, Chronic, B-Cell 560Squamous Cell Carcinoma of Head and Neck 550Lymphoma, Follicular 515Head and Neck Neoplasms 490Glioblastoma 473Small Cell Lung Carcinoma 447Lymphoma, Large B-Cell, Diffuse 440Triple Negative Breast Neoplasms 436Advanced Solid Tumors 432Leukemia 426Uterine Cervical Neoplasms 420Urinary Bladder Neoplasms 405

Interventions

Alpelisib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Lymphangioma × Clear all
NCT05948943 2026-06-02

EPIK-L1

Novartis

Phase 2/3 Recruiting
232 enrolled

Lymphangioma, Lymphangioma, Cystic, Lymphatic Abnormalities

NCT06239480 2026-03-27

SELVA

Palvella Therapeutics, Inc.

Phase 3 Active not recruiting
51 enrolled

Congenital Abnormalities, Lymphangioma, Lymphatic Abnormalities, Vascular Malformations

NCT05050149 2025-01-17

Study Evaluating the Safety and Efficacy of PTX-022 (QTORIN Sirolimus) in the Treatment of Microcystic Lymphatic Malformations

Palvella Therapeutics, Inc.

Phase 2 Completed
12 enrolled 7 charts

Lymphangioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡